Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations

Akin C, Fumo G, Yavuz AS, et al.

Haematologica · 2017

Grade Bcohortn=10
DOI ↗PubMed ↗

Key Findings

  • ●Imatinib efficacy in SM lacking exon 17 KIT mutations
  • ●Complete remission in 1 patient with K509I mutation

Referenced in (1 disease)

Systemic Mastocytosis
ID: pmid-28978170DOI: 10.3324/haematol.2017.172015PMID: 28978170